Bayer’s Vitrakvi (larotrectinib) Receives Health Canada Approval for Advanced Solid Tumors Harboring NTRK Gene Fusion

 Bayer’s Vitrakvi (larotrectinib) Receives Health Canada Approval for Advanced Solid Tumors Harboring NTRK Gene Fusion

Shots:

  • Vitrakvi has received approval under Health Canada’s NOC/c policy based on the clinical study evaluating Vitrakvi in adults and children with solid tumors harboring NTRK fusion
  •  The clinical study resulted in 75% ORR with 22% CR, 90% ORR is observed in children and 69% in adults. Vitrakvi therapy should be initiated following confirmation of NTRK gene fusion in a tumor specimen using a validated test
  • Vitrakvi is an oral selective TRK inhibitor act by shrinking the tumor or slowing/stopping its growth and has received FDA’s accelerated approval for solid tumors with NTRK gene fusion on Nov 26, 2018

Click here to­ read full press release/ article | Ref: Canada Newswire | Image: Financial Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post